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1. INTRODUCTION 
[1-4] 
The brain is the most complex part of the human body. It is the center of consciousness and 
controls all the voluntary and involuntary movement and bodily functions. It communicates with 
each part of the body through the nervous system, a network of channels that carry 
electrochemical signals.   
The belief that the brain is the organ that controls behavior has ancient roots, dating to early 
civilizations that connected loss of function to damage to parts of the brain and spinal cord. But 
the modern era of neuroscience began – and continues to progress – with the development of 
tools, techniques, and methods used to measure in ever more detail and complexity the structure 
and function of the nervous system. The modern era of neuroscience can be traced to the 1890s, 
when the Spanish pathologist Santiago Ramón y Cajal used a method developed by the Italian 
physician Camillo Golgi to stain nerve tissues to visualize the morphology and structure of the 
neurons and their connections. 
A person’s unique nervous system develops over the course of their lifespan in a way that 
resembles the evolution of nervous systems in animals across vast stretches of time. For 
example, the human nervous system begins developing even before a person is born. It begins as 
a simple bundle of tissue that forms into a tube and extends along the head-to-tail plane 
becoming the spinal cord and brain. 25 days into its development, the embryo has a distinct 
spinal cord, as well as hindbrain, midbrain and forebrain (Stiles & Jernigan, 2010). The brain is 
the headquarters of the entire nervous system and where most of your sensing, perception, 
thinking, awareness, emotions, and planning take place. The brain consumes 20% of the total 
oxygen and calories we consume even though it is only, on average, about 2% of our overall 
weight. 
Human brain development is a protracted process that begins in the third gestational week (GW) 
with the differentiation of the neural progenitor cells and continues till lifespan. The processes 
that contribute to brain development range from the molecular events of gene expression to 
environmental input. Both gene expression and environmental input are essential for normal 
brain development, and disruption of either can abruptly alter the neuronal outcomes. But neither 
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genes nor input is determinative of the possible outcome. Hence brain development is 
characterized as a complex series of dynamic and adaptive processes that operate throughout the 
process of development to promote the emergence and differentiation of new neural structures 
and functions. These processes operate within highly constrained and genetically organized, but 
constantly changes, over time, in order to support the emergence of the complex and dynamic 
structure of the human brain. 
Brain development begins with the foundational changes that occur during the embryonic period, 
which in humans extends through the eighth week post conception. By the end of the embryonic 
period the rudimentary structures of the brain and central nervous system are established and the 
major compartments of the central and peripheral nervous systems are defined. 
During this time there is rapid growth and elaboration of both cortical and sub cortical structures, 
including the rudiments of the major fiber pathways. Neuron production in humans begins on 
embryonic day E42, i.e. 42 days post conception and is largely complete by the middle of 
gestation. As neurons are produced they migrate to different areas of the brain where they begin 
to make connections with other neurons establishing rudimentary neural networks. At the end of 
the prenatal period major fiber pathways, thalamic-cortical pathway becomes complete. 
Structural changes in both the major gray and white matter compartments follows through 
childhood and adolescence, and these structural changes also parallels with the changes in 
functional organization that are being reflected in the behavior. During the early postnatal period, 
level of connectivity throughout the developing brain far exceeds that of adults. This 
connectivity is gradually pruned back via competitive processes that are influenced by the 
experience of the organism. 
Neurological problems may occur slowly and cause a gradual loss of function (degenerative). Or 
they may occur suddenly and cause life-threatening problems (acute). Symptoms may be mild or 
severe. Some serious conditions, diseases, and injuries that can cause nervous system problems 
include: 
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 Epilepsy – storms of abnormal electrical activity in the brain causing seizures 
 Meningitis – inflammation of the membrane covering the brain 
 Multiple sclerosis – the myelin sheaths protecting the electrical cables of the central 
nervous system are attacked 
 Cerebral palsy – inability to coordinate and control movement and body posture 
 Sciatica – pressure on a nerve caused by a slipped disc in the spine or arthritis of the 
spine and, sometimes, other factors 
 Shingles – infection of sensory nerves caused by the varicella-zoster virus 
 Stroke – a lack of blood to part of the brain. 
Hundreds of millions of people worldwide are affected by neurological disorders. More than 6 
million people die because of stroke each year; over 80% of these deaths take place in low- and 
middle-income countries. More than 50 million people have epilepsy worldwide. It is estimated 
that there are globally 47.5 million people with dementia with 7.7 million new cases every year - 
Alzheimer's disease is the most common cause of dementia and may contribute to 60–70% of 
cases
[5]
. 
 
 
 
 
 
 
 
 
 
 
A Comparative Study on the Neuro-protective Effects of DHA, Vitamin-E And Memantine in the 
Neonatal Rat model Of LPS Induced Cerebral Palsy. 
 
Department of Pharmacology Page 4 
 
1.1 . NEURO-DEVELOPMENTALDISORDERS [6-8] 
Neurodevelopment is the process of proliferation of the radial glial cells of the brain and the 
neurons starting from the 2
nd 
month of gestation and continues to develop in the postnatal years. 
This process is complete only at the age of 3 years, which occurs within the cerebellum 
postnatally. 
Synapse formation and myelination are the two significant processes that are responsible for the 
complete neurodevelopmental process. Formation of synapse is essential in the last trimester and 
first 2 years of life, which is significant in functioning and development of the nervous system. 
Myelin sheath which acts as the protective covering over the neuronal cells begins in the second 
half of gestation and continue still adolescence, with different systems myelinating at different 
period of time. 
The brain's center of reasoning and problem solving is among the last to mature. The decade-
long MRI study of normal brain development shows that "higher-order" brain centers, such as 
the prefrontal cortex, don't fully develop until young adulthood. 
Cortex areas can be seen maturing at ages in which relevant cognitive and functional 
developmental milestones occur. The first areas to mature (e.g. extreme front and back of the 
brain) are those with the most basic functions, such as processing the senses and movement 
followed by areas involved in spatial orientation and language (parietal lobes). 
Areas with more advanced functions such as integrating information from the senses, reasoning 
and other "executive" functions in the prefrontal cortex matures later. 
Tremendous rate of growth in areas of vision and sensation occur in the early school years. In 
middle school areas in language development shows rapid growth. Late teens exhibit rapid 
growth in areas controlling inhibition, judgment. Healthy development means an increase and 
loss of neurological tissue. 
Maturation of the central nervous system is critical in the development of neurodevelopmental 
disorders. Cell pruning or synapse pruning, which occurs between the ages of 5 – 20 years 
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appears to be a critical process whereby if increased may be linked with childhood onset 
schizophrenia and if decreased may be linked with autism. 
 
 
1.2. NEURODEVELOPMENTAL & INTELLECTUAL DISORDERS 
[9,10]
 
 
Neurodevelopmental disorders are disabilities in the functioning of the brain or the nervous 
system that affect a child’s behavior, memory or ability to learn e.g. mental retardation, dyslexia, 
cerebral palsy, attention deficit hyperactivity disorder (ADHD), learning deficits and autism. 
 
Recent study says that1 in 6 children in the developed countries were affected by, 
 Cerebral palsy 
 IQ 
 Learning disabilities 
 Attention deficit hyperactivity disorder (ADHD) 
 Autism 
 Developmental delay 
 
Neurodevelopmental behavioral disorders were more prevalent in the developing countries and 
statistics shows that15% of children are described as suffering from learning disabilities, 
developmental delay, attention deficit hyperactivity disorder, autism, reduced intelligence 
quotient and cerebral palsy. 
In Aboriginal children, the prevalence is often much higher. In some cases etiology was directly 
linked to identified exposures, e.g. fetal alcohol, tobacco smoke, low birth weight and obstetric 
complications, in most cases specific etiology is unknown. 
 
Co-morbidity and adult outcomes of failed neurodevelopment are as follows, 
 Anxiety/depression, oppositional defiant disorder, bipolar disorder, Tourette’s Syndrome. 
 Substance abuse, antisocial behavior, and even criminality are among the better-known 
problems persisting into adulthood 
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1.3. ENVIRONMENTAL LINKAGES OF NEURODEVELOPMENTAL 
PROCESSES 
 Proliferation 
Proliferation of neurons from the early development stage and through-out the lifetime of 
the individual may be affected on consumption of, 
 Alcohol 
 Methyl mercury 
 Chlorpyrifos  
 
 Migration of Neuroblasts -  
Neuronal migration is the method by which neurons travel from their origin or birthplace 
to their final position in the brain. 
 X-ray irradiation 
 Ethanol 
 
 Differentiation of Neuroblasts -  
The process of development and differentiation of the neural tube into permanent cellular 
elements are disrupted by, 
 Ethanol 
 Nicotine 
 Methylmercury 
 Lead 
 
 Neurotransmission processes -  
Transmission of neuronal signal or impulses that are transmitted actively by means of 
neurotransmitters are blocked by, 
 Cholinesterase inhibitors 
 Ethanol 
 Aluminum 
 Pharmaceuticals and pesticides designed to target specific neurotransmitter systems 
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 Synaptogenesis - 
Exuberant synaptogenesis means an explosion of the synapse formation may affect an 
healthy individual at the early stages of the brain development. It may be caused due to 
following, 
 Ethanol 
 Lead 
 Polychlorinated biphenyls (PCBs), triethyltin, parathion, permethrin, and 
Serotonin antagonist. 
 Apoptosis or cell death 
Apoptosis is a complex process in which appropriate cells are removed to ensure optimal 
neurodevelopmental behavioral intellectual development. And this process is adversely 
affected at critical stages of gestation and postnatal development. 
 Apoptosis is mediated on intake of, 
 Ethanol 
 Lead 
 Mercury and Chlorpyrifos. 
 
1.4. PREVALENCE OF NEURODEVELOPMENTAL DISORDER 
[4, 5] 
The EPIPAGE study –that has been designed to investigate outcomes of preterm children over 
the past 15 years – 
 Identified 5,567 infants born at 22 to 34 weeks' gestation in 2011 in France. 
 Rates of survival without severe or moderate neuromotor and sensory disabilities at 2 
years of age were 48.5% for children born at 22-26 weeks' gestation, 90% at 27-31 
weeks' gestation, and 97.5% at 32-34 weeks' gestation. 
 Only one child born at 22-23 weeks' gestation survived. 
 
Upon consideration of the baseline characteristics of infants, survival rate and survival without 
severe or moderate neuromotor and sensory disabilities at rose between 1997 and 2011 for 
children born at 22-31 weeks' gestation, but there was no change observed for children born at 24 
weeks' gestation. 
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 Rates of cerebral palsy decreased by 3.3% during 1997-2011 which was statistically 
significant, at both 24-31 and 32-34 weeks of gestation. 
 
1.4.1. Developmental delay 
Upon exclusion of the children suffering from other neurological disorders, 50%, 41%, and 36% 
of children born at 24-26, 27-31, and 32-34 weeks' gestation, respectively were considered at risk 
of developmental delay. Delays in language development as well as poorer social-emotional 
competence most frequently scored below threshold. 
Even though the improvements were made in neuromotor and sensory outcomes, a high number 
of babies born before 34 weeks are prone to developmental delay. 
 
2. LITERATURE REVIEW
 
2.1. CEREBRAL PALSY 
[6, 8]
 
Cerebral palsy is the most common cause of motor disability in children and also affects a large 
population.  The worldwide incidence being 2 to 2.5 per 1000 live births The term cerebral palsy 
describes a group of movement disorders caused by an injury or infection by micro-organism or 
disturbance in the early developing brain and specifically the areas involved with creating, 
coordinating and controlling movement and posture
(1)
. 
 
It may be stated as a static encephalopathy in which, even though the primary lesion, anomaly or 
injury is static, the clinical pattern of presentation may change with time due to growth and 
developmental plasticity and maturation of the central nervous system. 
 
2.2. TERMS AND CONCEPTS 
Cerebral palsy (CP)
1 
describes a group of permanent
2 
disorders
3 
of the development
4
 of 
movement and posture
5
 causing
6 
activity limitation
7
, that are attributed
8
 to non-progressive
9 
disturbance
10
 that occurred in the developing fetal or infant
11 
brain
12
.The motor disorders of 
cerebral palsy are often accompanied by
13
 disturbances of sensation
14
, perception
15
, cognition
16 
communication
17
, and behavior
18
, by epilepsy
19
, and by Secondary musculoskeletal problems
20
.
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1. ‘Cerebral palsy (CP)’ – 
The term describes a prevalent, clinically important and identifiable group of persons with 
neurodevelopmental disabilities, the term ‘cerebral palsy’ is established in the literature and is 
used universally by clinicians, therapists, epidemiologists, researchers, policy makers, health 
care funding organization and laypersons. The term ‘CP has, however, been, indicating the need 
for an internationally acceptable definition. 
 
2. ‘permanent’ – 
This definition excludes transient disorders, but recognizes that children and adults have 
changing patterns of clinical manifestations that are permanent. 
 
3. ‘disorders’ – 
This refers to conditions in which there is disruption of the usual orderly stages of child 
development. 
 
4. ‘development’ – 
The ‘developmental’ aspect of CP is also important with regard to management strategies that 
may include interventions that address the developmental consequences. The motor impairments 
of children eventually diagnosed with CP begin to manifest very early in child development, 
usually before 18 months of age, with delayed or aberrant motor progress; other 
neurodevelopmental and functional difficulties may occur. The clinical picture of CP evolves 
with time, development, learning, activities, therapies, ageing, and other factors. 
 
5. movement and posture– 
Abnormal gross and fine motor functioning and organization (reflecting abnormal motor control) 
are the core features of CP. These motor problems lead to difficulties with walking, feeding and 
swallowing, coordinated eye movements, articulation of speech, and secondary problems with 
behaviour, musculoskeletal function, and participation in society 
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6. ‘causing’ – 
Activity limitations are presumed to be a consequence that are caused of the motor disorder. 
Thus, disorders of movement and posture that are not associated with activity limitations are not 
considered to be part of the CP group. 
 
7. ‘activity limitation’ –  
According to World Health Organization’s(WHO), International Classification of Functioning, is 
defined as  Disability ‘activity’ as the execution of a task or 
action by an individual”, and identifies ‘activity limitation’ as “difficulties an individual may 
have in executing activities”. 
 
8. ‘attributed to’ – 
Understanding of various forms of developmental neurobiology(including genetic, biochemical, 
and other influences on brain development) is increasing rapidly, such that 
it is becoming possible to identify structural and other evidence of poor brain development in 
people with CP. Otherwise discovery would have been elusive. 
 
09. ‘non-progressive’ – 
The term non-progressive is used to denote that the pathophysiological mechanisms leading to 
CP are presumed to arise from a single. The inciting event that results in the partial disruption of 
the brain functions includes events that are associated with changing or new manifestations that 
are superimposed on one-another neurodevelopmental process. Not all the motor dysfunctions 
are considered as Cerebral palsy. 
 
10. ‘disturbances’ – 
Disturbances are the events that may cause interruption, damage, or may affect the normal 
functioning of the brain development. It poses a major problem 
 
11. ‘fetal or infant’- 
The disturbances that occur very early in human biological development impact much on the 
development of motor function than disturbances that occur during later adolescence. 
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12. ‘Brain’ – 
The term ‘brain’ includes the cerebrum, the cerebellum and the brain stem. It excludes motor 
disorders that comprises of spinal, peripheral nerve, muscular or mechanical origin. 
 
13. ‘Accompanied by’ – 
Along with motor and sensory disorders, other neurodevelopmental disorders may also occur. 
 
14. ‘Sensation’ – 
Vision, hearing and other sensory functions are affected, and as a secondary consequence of 
activity limitations that restrict learning and perceptual development experiences. 
 
15. ‘Perception’ – 
The capacity to incorporate and interpret sensory and/or cognitive information may be impaired 
both as a function of the ‘primary’ disturbance(s) to which CP is attributed, and as a secondary 
consequence of activity limitations that restrict learning and perceptual development 
experiences. 
 
16. ‘Cognition’ – 
Cognitive processes are affected, both as a function of the ‘primary’ disturbance and as a 
secondary consequence of activity that restricts learning and perceptual development 
experiences. 
 
17. ‘communication’-  
Expressive and receptive communication may be affected, both as a function of the primary 
disturbance to which CP is attributed, and as a secondary consequence of activity that restricts 
learning and perceptual development experiences. 
 
18. ‘behaviour’ – 
This includes psychiatric or behavioural problems such as autistic spectrum disorders, ADHD, 
sleep disturbances, mood and anxiety disorders 
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19. ‘epilepsy’- 
Epilepsies are seen in persons with cerebral palsy as multitude of neuron firing. 
 
20. ‘secondary musculoskeletal problems’ – 
People with CP may develop a variety of musculoskeletal problems, such as muscle/tendon 
contractures, bony torsion, hip displacement, 
spinal deformity. Many of these problems develop throughout life and are related to physical 
growth, muscle spasticity, ageing and other factors. 
 
2.3. HISTORY OF CEREBRAL PALSY 
[9]
 
Since the 1830s, cerebral palsy’s physiological details and some of its cause were uncovered by 
numerous doctors, clinical investigators, and other experts though several mysteries about its 
causes still remain. 
 
1830’s: British surgeon William John Little defined what is now known to be as “cerebral 
palsy.” He was partially disabled by polio, and spent most of his medical career studying various 
disabling conditions, including spastic diplegia, which was identified as a form of cerebral palsy. 
1853: William John little published a research titled “On the Nature and Treatment of the 
Deformities of the Human Frame.” He described various neonatal injuries and congenital 
disabilities that affect the muscular system. He also wrote the first description of pseudo 
hypertrophic muscular dystrophy. 
1861: William John little created the first definition of cerebral palsy, referring to the birth 
injuryas a result of difficulties during labor in which “the child has been partially suffocated.” 
Since no one else had written about spasticity or variation in muscle tone, the term “cerebral 
palsy” still didn’t exist. Instead, the disability is referred to as Little’s Disease. Little’s research 
paper also discussed the importance of early treatment and intervention. Little wrote about how 
the children have been “restored to considerable activity and enjoyment of life.” 
1889: Sir William Osler wrote a book titled Cerebral Palsies of Children. Osler didn’t refer to 
the disability as Little’s Disease, but instead built upon Little’s work and added to it from his 
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own scientific findings. Osler chose to base the term “cerebral palsy” on the Latin words for 
“brain” and “paralysis” rather than use common English vernacular. 
1892: William Osler became the Chief of Medicine at Baltimore’s Johns Hopkins Medical 
School. He published a text titled The Principles and Practice of Medicine: Designed for the Use 
of Practitioners of Students of Medicine. The textbook became a standard work that was studied 
for the next 40 years. Osler’s work also helped establish credibility for his studies on cerebral 
palsy.. 
1897: Austrian neurologist and psychiatrist Sigmund Freud is the first medical researcher to 
disagree with the theories put forward by Drs. Little and Osler. Freud suggested that cerebral 
palsy was a brain-related disease that affects children before birth (not during or after as Little 
proposed). Freud also associated various disorders, including intellectual disabilities, visual 
disturbances, and seizures, with cerebral palsy  . 
1949: The United Cerebral Palsy Foundation (UCP) is founded by Leonard Goldenson, president 
of United Paramount Theaters and the ABC television network, and his wife Isabelle in a joint 
effort with prominent New York businessman Jack Hausman and his wife Ethel. Both couples 
are parents of children with cerebral palsy and use their influence to create a foundation to help 
others affected by the disability. 
1952: Marie Killilea wrote Karen, the first of two nonfiction books about the author’s 
experiences while caring for her daughter Karen, who was born with cerebral palsy. Karen and 
its sequel, With Love From Karen (1963) became best sellers. Killilea also wrote Wren (1954), a 
children’s version of Karen’s story. 
1963: President John F. Kennedy signed the Community Mental Health Act. The law stipulates 
that children with mental disabilities can be cared for in the community instead of having to be 
institutionalized. 
1980’s: Medical researchers prove Freud’s theory that cerebral palsy can happen before birth. In 
addition, clinical studies confirm that cerebral palsy can also be caused by birth injuries, though 
it only makes up less than 10% of all diagnosed cases. 
1990: Congress passed the Americans with Disabilities Act (ADA), a federal law that  prohibits 
employers from carrying out discriminatory hiring practices against individuals with disabilities. 
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2.4. ETIOLOGY OF CEREBRAL PALSY 
[9, 10] 
Congenital Cerebral Palsy Causes 
If an infant develops cerebral palsy before or during childbirth, it’s considered congenital CP. 
This form of CP is marked by development before birth. Per the Centers for Disease Control and 
Prevention (CDC), congenital CP is the most common form of cerebral palsy.   
 
Fig no. 01 Pathogenesis of Cerebral palsy 
 
The most common causes of congenital CP include: 
 Infections While Pregnant: Infections such as cytomegalovirus (CMV), chicken 
pox,  and rubella may increase the chances of an infant developing CP as these diseases 
increase cytokines, tiny proteins that act as receptors in the body. When cytokines are 
released in substantial amounts, it can lead to infant brain damage, which in turn can lead 
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to CP. Mothers with high fevers and/or a urinary tract infection also run the risk of their 
infant developing CP. 
 Twins or Multiple Births: The birth of more than one baby increases the chances of CP 
due to, in most cases, low birth weight. 
 Low Birth Weight: Infants under five pounds are at an increased risk of developing CP, 
with infants under three pounds being the highest risk group. Since most infants who are 
born prematurely typically weigh five pounds of less, premature babies are also at risk. 
 Infertility Treatments: Since many infants born after infertility treatments tend to be 
born premature with low birth weights, the risk for CP is increased. 
 Jaundice: There is a common misconception that jaundice is a minor medical that won’t 
pose any long-term medical problems. However, if left untreated, jaundice can cause a 
host of serious problems, including a heightened risk of developing CP. 
 Birth Problems: Uterine rupture, placental problems, and umbilical cord problems can 
all lead to an increased risk of the infant developing CP. 
 Chorioamnionitis: A study performed by San Diego’s University of California revealed 
that chorioamnionitis present in the womb during pregnancy increases the risk of an 
infant developing CP by up four times. 
 Incompatible Blood: Incompatibility of blood types between a mother and infant can 
lead to Rh factor diseases, increasing the risk of CP. However, if a physician detects the 
blood incompatibility in time, the mother can be given a Rh immune globulin injection 
starting at around the 28 week of pregnancy. 
 Periventricular leukomalacia (PVL) 
PVL is a kind of damage that affects the brain's white matter because of a lack of oxygen in the 
womb. 
It may occur if the mother has an infection during pregnancy, such as rubella or German measles, 
low blood pressure, preterm delivery, or if she uses an illegal drug. 
 Asphyxia during labor and delivery – Until recently, it was widely believed that 
asphyxia (lack of oxygen) during a difficult delivery was the cause of most cases of 
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cerebral palsy. The ACOG/AAP report shows that fewer than 10 percent of the types of 
brain injuries that can result in cerebral palsy are caused by asphyxia. 
Acquired Cerebral Palsy Causes: 
Acquired CP occurs when an infant develops brain damages at least 28 days or more after birth. 
Acquired CP happens much less often when compared to congenital CP. In fact, acquired CP 
affects around 20% of all people who’ve developed the disorder. The most common causes 
include: 
 Low Birth Weight: Similar to congenital CP, low birth also increases the risk of 
acquired CP. 
 Blood Flow Problems: Blood flow problems, particularly to the brain, heightens the risk 
of acquired CP. Common blood flow problems to brain can occur because of blood 
clotting, unformed blood vessels, sickle cell diseases, and/or heart defects. 
 Traumatic Head Injuries: Traumatic head injuries can happen when an infant is 
dropped, is in an accident, or falls. If brain damage occurs after a traumatic brain injury, 
acquired CP may follow. 
Brain Damage 
Brain damage whether before, during, or after birth can lead to CP. In the past, many physicians 
believed that CP was related to brain damage that occurred during birth because of asphyxiation. 
This in part is true, with at least 1 out of every 10 infants developing CP after suffering from 
asphyxiation. However, recent research shows that brain damage that occurs before birth can 
also lead to CP. There are a few different ways that brain damage occurs during birth that 
heightens the risk of developing CP. 
Mothers must be monitored frequently during pregnancy, especially if they have any infections 
or high blood pressure. Both infections and high blood pressure may lead to infant brain damage, 
which in turn can lead to CP. In addition, abnormal brain development during pregnancy can 
lead to CP. Abnormal brain development can occur due to a maternal infection, mutations in the 
genes, or trauma to the baby’s head. 
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Medical Negligence 
Even though several cases of CP are caused without reason, there are many instances in which 
physicians failed to properly identify medicals issues and/or failed to use the correct actions 
during and birth birth to reduce the risk. The most common reasons CP occurs because of 
medical negligence include: 
 Failure to properly monitor and asses the fetal heartbeat during and after delivery 
 Failure to schedule and provide a timely C-section 
 Failure to detect and treat maternal infections 
 Failure to use birth-assisting tools correctly, such as forceps or a vacuum extraction tool 
 Failure to correct umbilical cord problems, such as a prolapsed cord 
 Failure to supply oxygen in a timely manner to an asphyxiated infant 
 Failure to monitor respiratory and oxygen treatments 
Intracranial hemorrhage 
Sometimes, bleeding inside the brain happens when a fetus experiences a stroke. 
Bleeding in the brain can stop the supply of blood to vital brain tissue, and this tissue can 
become damaged or die. The escaped blood can clot and damage surrounding tissue. 
Several factors can cause a stroke in a fetus during pregnancy: 
 a blood clot in the placenta that blocks the flow of blood 
 a clotting disorder in the fetus 
 interruptions in arterial blood flow to the fetal brain 
 untreated pre-eclampsia in the mother 
 inflammation of the placenta 
 pelvic inflammatory infection in the mother 
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During delivery, the risk is increased by the following factors: 
 emergency cesarean 
 the second stage of labor is prolonged 
 vacuum extraction is used during delivery 
 fetal or neonatal heart anomalies 
 umbilical cord abnormalities 
 
2.5. SYMPTOMS 
[11] 
An infant with cerebral palsy may have muscular and movement problems, including poor 
muscle tone. Muscle tone refers to a person's automatic ability to tighten and relax muscle when 
required. 
Features can include: 
 overdeveloped or underdeveloped muscles, leading to stiff or floppy movements 
 poor coordination and balance, known as ataxia 
 involuntary, slow writhing movements, or athetosis 
 stiff muscles that contract abnormally, known as spastic paralysis 
 crawling in an unusual way 
 lying down in awkward positions 
 favoring one side of the body over the other 
 a limited range of movement 
Other signs and symptoms include: 
 late achievement of developmental milestones such as crawling, walking, or speaking 
 hearing and eyesight problems 
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 problems controlling bladder and bowel movements 
 seizures 
 drooling, and problems with feeding, sucking, and swallowing 
 being easily startled 
Symptoms normally start to show during the first 3 years of life. 
2.6. CLASSIFICATION OF CEREBRAL PALSY 
[12] 
 
Below are the most commonly used classification systems understood and used by qualified 
practitioners. 
 Classification based on severity level 
 Classification based on topographical distribution 
 Classification based on motor function 
 Classification based on gross motor function classification system 
  
1. Classification based on severity level 
Cerebral Palsy is often classified by severity level as mild, moderate, severe, or no CP. These are 
broad generalizations that lack a specific set of criteria. 
Even when doctors agree on the level of severity, the classification provides little specific 
information, especially when compared to the GMFCS. Still, this method is common and offers a 
simple method of communicating the scope of impairment, which can be useful when accuracy 
is not necessary. 
Mild –  
Mild Cerebral Palsy means a child can move without assistance; his or her daily activities are not 
limited. 
Moderate –  
Moderate Cerebral Palsy means a child will need braces, medications, and adaptive technology 
to accomplish daily activities. 
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Severe –  
Severe Cerebral Palsy means a child will require a wheelchair and will have significant 
challenges in accomplishing daily activities. 
 
No CP – 
No CP means the child has Cerebral Palsy signs, but the impairment was acquired after 
completion of brain development and is therefore classified under the incident that caused the 
Cerebral Palsy, such as traumatic brain injury or encephalopathy. 
 
2. Classification based on topographical distribution 
Topographical classification describes body parts affected. The words are a combination of 
phrases combined for one single meaning. When used with Motor Function Classification 
System, it provides a description of where and to what extent a child is affected by Cerebral 
Palsy. This method is useful in ascertaining treatment protocol. 
 Paresis means weakened 
 Plegia/Plegic means paralyzed 
The prefixes and root words are combined to yield the topographical classifications commonly 
used in practice today. 
1. Monoplegia/monoparesis 
Only one limb is affected. It is believed this may be a form of hemiplegia/hemiparesis where one 
limb is significantly impaired. 
 
2. Diplegia/diparesis  
Indicates the legs are affected more than the arms; primarily affects the lower body. 
 
3. Hemiplegia/hemiparesis  
Indicates the arm and leg on one side of the body are affected. 
4. Paraplegia/paraparesis  
The lower half of the body, including both legs, is affected. 
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5. Triplegia/triparesis  
Indicates three limbs are affected. This could be both arms and a leg, or both legs and an 
arm. Or, it could refer to one upper and one lower extremity and the face. 
6. Double hemiplegia/double hemiparesis 3 
Indicates all four limbs are involved, but one side of the body is more affected than the 
other. 
7. Tetraplegia/tetraparesis  
Indicates that all four limbs are involved, but three limbs are more affected than the 
fourth. 
8. Quadriplegia/quadriparesis  
Means that all four limbs are involved. 
9. Pentaplegia/pentaparesis  
Means all four limbs are involved, with neck and head paralysis often accompanied by 
eating and breathing complications 
 
3. Classification based on motor function 
The brain injury that causes Cerebral Palsy affects motor function, the ability to control the body 
in a desired matter. Two main groupings include spastic and non-spastic. Each has multiple 
variations and it is possible to have a mixture of both types. 
1. Spastic Cerebral Palsy is characterized by increased muscle tone. 
2. Non-spastic Cerebral Palsy will exhibit decreased or fluctuating muscle tone. 
 
Motor function classification provides both a description of how a child’s body is affected and 
the area of the brain injury.  
Muscle tone 
Many motor function terms describe Cerebral Palsy’s effect on muscle tone and how muscles 
work together. Proper muscle tone when bending an arm requires the bicep to contract and the 
triceps to relax. When muscle tone is impaired, muscles do not work together and can even work 
in opposition to one another. 
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Two terms used to describe muscle tone are: 
1. Hypertonia/Hypertonic — increased muscle tone, often resulting in very stiff limbs. 
Hypertonia is associated with spastic Cerebral Palsy 
 
2. Hypotonia/Hypotonic — decreased muscle tone, often resulting in loose, floppy limbs. 
Hypotonia is associated with non-spastic Cerebral Palsy 
 
Two classifications by motor function: pyramidal (spastic) and extrapyramidal (non-spastic) 
When referring to location of the brain injury, spastic and non-spastic Cerebral Palsy is referred 
to in the medical community as pyramidal and extrapyramidal Cerebral Palsy. 
1. Pyramidal, or spastic Cerebral Palsy  
The pyramidal tract consists of two groups of nerve fibers responsible for voluntary 
movements. They descend from the cortex into the brain stem.  
2. Extrapyramidal, or non-spastic Cerebral Palsy 
Indicates the injury is outside the tract in areas such as the basal ganglia, thalamus, and 
cerebellum. Pyramidal and extrapyramidal are key components to movement 
impairments. Non-spastic Cerebral Palsy is decreased and/or fluctuating muscle tone. 
Multiple forms of non-spastic Non-spastic Cerebral Palsy is divided into two groups, 
ataxic and dyskinetic.  
 Ataxia 
 Dyskinetic 
 
1. Ataxic/ataxia 
Ataxic Cerebral Palsy affects coordinated movements. Balance and posture are involved. 
Walking gait is often very wide and sometimes irregular. Control of eye movements and depth 
perception can be impaired. Often, fine motor skills requiring coordination of the eyes and 
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hands, such as writing, are difficult. Does not produce involuntary movements, but instead 
indicates impaired balance and coordination 
2. Dyskinetic 
Dyskinetic Cerebral Palsy is separated further into two different groups; athetoid and dystonic. 
a) Athetoid Cerebral Palsy includes cases with involuntary movement, especially in the 
arms, legs, and hands. 
b) Dystonia/Dystonic Cerebral Palsy encompasses cases that affect the trunk muscles more 
than the limbs and results in fixed, twisted posture.Because non-spastic Cerebral Palsy is 
predominantly associated with involuntary movements, some may classify Cerebral Palsy 
by the specific movement dysfunction, such as: 
c) Athetosis — slow, writhing movements that are often repetitive, sinuous, and rhythmic 
d) Chorea — irregular movements that are not repetitive or rhythmic, and tend to be more 
jerky and shaky 
e) Choreoathetoid — a combination of chorea and athetosis; movements are irregular, but 
twisting and curving 
f) Dystonia — involuntary movements accompanied by an abnormal, sustained posture 
 
3. Mixed 
A child’s impairments can fall into both categories, spastic and non-spastic, referred to as mixed 
Cerebral Palsy. The most common form of mixed Cerebral Palsy involves some limbs affected 
by spasticity and others by athetosis 
04. Classification based on Gross Motor Function Classification System 
Gross Motor Function Classification System, or GMFS, uses a five-level system that corresponds 
to the extent of ability and impairment limitation. A higher number indicates a higher degree of 
severity. Each level is determined by an age range and a set of activities the child can achieve on 
his or her own. 
The GMFCS is a universal classification system applicable to all forms of Cerebral Palsy. When 
the child fits in multiple levels, the lower of the two classification levels is chosen. The GMFCS 
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classification system recognizes that children with impairments have age-appropriate 
developmental factors. GMFCS is able to chart by age group (0-2; 2-4; 4-6; 6-12; and 12-18) a 
developmental guideline appropriate for the assigned GMFCS level. It emphasizes sitting, 
movement transfers and mobility, charting independence and reliance on adaptive technology. 
Cerebral Palsy is often classified by severity level as mild, moderate, severe, or no CP. These are 
broad generalizations that lack a specific set of criteria. 
GMFCS classification, 
1. GMFCS Level I – walks without limitations. 
2. GMFCS Level II – walks with limitations. Limitations include walking long distances and 
balancing, but not as able as Level I to run or jump; may require use of mobility devices 
when first learning to walk, usually prior to age 4; and may rely on wheeled mobility 
equipment when outside of home for traveling long distances. 
3. GMFCS Level III – walks with adaptive equipment assistance. Requires hand-held 
mobility assistance to walk indoors, while utilizing wheeled mobility outdoors, in the 
community and at school; can sit on own or with limited external support; and has some 
independence in standing transfers. 
4. GMFCS Level IV – self-mobility with use of powered mobility assistance. Usually 
supported when sitting; self-mobility is limited; and likely to be transported in manual 
wheelchair or powered mobility. 
5. GMFCS Level V – severe head and trunk control limitations. Requires extensive use of 
assisted technology and physical assistance; and transported in a manual wheelchair, unless 
self-mobility can be achieved by learning to operate a powered wheelchair. 
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2.7.PATHOPHYSIOLOGY OF CEREBRAL PALSY 
[13]
 
 
The causal factors for CP are multiple and are linked. CP can follow a brain abnormality that 
occurs pre, peri, or postnatally. Even when the injury occurs at a defined time, moderating 
factors may also exist. The risk factors for CP include: preterm birth, intra-uterine growth 
restriction, maternal/fetal infection, inflammation, perinatal and intrapartum difficulties (e.g., 
hypoxic–ischemic insult), and genetic predispositions. Remarkably, intrapartum hypoxia–
ischemia (HI) is thought to account for only 14.5% of CP cases.  
2.7.1. PRETERM BIRTH 
[14] 
The premature neonatal brain is susceptible to two main pathologies: intraventricular 
hemorrhage (IVH) and periventricular leukomalacia (PVL). Although both pathologies increase 
the risk of CP, PVL is more closely related to CP and is the leading cause in preterm infants. The 
term PVL describes white matter in the periventricular region that is underdeveloped or damaged 
(“leukomalacia”). Both IVH and PVL cause CP because the corticospinaltracts, composed of 
descending motor axons, course through the periventricular region. 
A. Intraventricular hemorrhage (IVH) 
IVH describes bleeding from the sub-ependymal matrix (the origin of fetal brain cells) into the 
ventricles of the brain. The blood vessels around the ventricles develop late in the third trimester, 
thus preterm infants have underdeveloped periventricular blood vessels, resulting in the 
increased risk of IVH. The risk of cerebral palsy increases with the severity of IVH. 
 
B. Periventricular leukomalacia (PVL) 
IVH is a risk factor for PVL, but PVL is a separate pathological process. The pathogenesis of 
PVL arises from two important factors:  
(1) Ischemia/hypoxia  
(2) infection/inflammation 
A Comparative Study on the Neuro-protective Effects of DHA, Vitamin-E And Memantine in the 
Neonatal Rat model Of LPS Induced Cerebral Palsy. 
 
Department of Pharmacology Page 26 
 
 
Fig no. 02 Cerebral palsy and Periventricular Leukomalacia 
 
 
Fig no. 03 Neonatal stroke and H/I encephalopathy 
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1. Hypoxia/ischemia  
The periventricular white matter of the neonatal brain is supplied by the distal segments 
of adjacent cerebral arteries. Blood flow from two arterial sources protects the white 
mater when one artery is blocked, this watershed zone is susceptible to damage from 
cerebral hypoperfusion i.e., decreased cerebral blood flow in the brain. 
Since preterm and even term neonates have low cerebral blood flow, the periventricular 
white matter is susceptible to ischemic damage. 
 
2. Infection and inflammation  
Process of infection and inflammation involves microglial (brain 
macrophage)cellactivation and cytokine release, which causes damage to a specific cell 
type in the developing brain called the oligodendrocyte. The oligodendrocytes are a type 
of supportive brain cell that wraps around neurons to form the myelin sheath, which is 
essential for white matter development.  
Intrauterine infections activate the fetal immune system, which produces cytokines (e.g., 
interferon γ and TNF-α) that are toxic to premyelinatingoligodendrocytes. Infections also 
activate microglial cells, which release free radicals. Premyelinatingoligodendrocytes 
have immature immunity against reactive oxygen species (e.g., low production 
of glutathione, an important antioxidant). IVH is hypothesized to cause PVL because 
iron-rich blood causes iron-mediated conversion of hydrogen peroxide to hydroxyl 
radical, contributing to oxidative damage. 
 
2.7.2. EXCITOTOXICITY 
[15] 
It is a process where increased extracellular glutamate levels stimulate oligodendrocytes to 
increase calcium influx, which stimulates reactive oxidative species release. Glutamate is 
increased because hypoxia causes white matter cells to reduce reuptake of glutamate due to lack 
of energy to operate glutamate pumps. Glutamate is also released from microglial cells during 
the inflammatory response. 
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Fig no. 04 Events that leads to Cerebral palsy 
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2.8. TREATMENT 
[16]
 
Treating Cerebral Palsy is almost as complex as the condition is, and there’s no specific 
approach because each individual is affected differently. Although the brain injury that causes 
Cerebral Palsy cannot be healed, the resulting physical impairment can be managed with a wide 
range of treatments and therapies. Although there is no universal protocol developed for all 
cases, a person’s form of Cerebral Palsy, extent of impairment, and severity level help to 
determine care. 
There is no present approach to totally prevent or cure CP but many treatments have been 
developed that can help reduce its impact on the patient’s quality of life. As with many diseases, 
it is best that treatments are initiated early in the course of the disease.  
This is especially true with a progressive disease such as CP with limited windows for 
interventions. Current treatments include physical and occupational therapy and device or 
equipment to help with mobility and coordination, medications to alleviate motor symptoms. 
While therapy and adaptive equipment are the primary treatment protocol for Cerebral Palsy, an 
individual may also require drug therapy and surgical interventions.  
 
2.8.1. DRUGS IN TREATMENT OF CP
 [17]
 
Children who experience seizures, spasticity, and unwanted or uncontrolled movements, such as 
athetosis and chorea, are prescribed drugs to minimize the movements. Some medications are 
used to relax muscles, increase comfort and facilitate better posture. 
The most common medications used to treat Cerebral Palsy include medications within these 
categories: 
 Anticholinergics (uncontrolled body movements) 
 Anticonvulsants (seizure medications) 
 Antidepressants (depression medications) 
 Antispastic (muscle relaxers) 
 Anti-inflammatories (pain management) 
 Stool softeners 
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01. Anticholinergics 
Anticholinergic medications are used to treat uncontrolled body movements such as muscle 
stiffness, tremors and spasms, as well as drooling associated with non-spastic Cerebral Palsy. In 
large doses, some anticholinergics can stimulate the nervous system; in small doses the drug can 
act as a depressant. 
Some forms of Cerebral Palsy where anticholinergics may also be prescribed include: 
 Athetosis – slow, writhing movements that are often repetitive and involuntary 
 Chorea – jerky, involuntary, irregular and uncontrollable movements 
 Choreoathetoid – a combination of chorea and athetosis, where movements are jerky, 
twitching, slow and writhing 
 Dystonia – prolonged, involuntary contractions that result in twisting motions, tremors and 
abnormal posture 
These drugs work by blocking the neurotransmitter that causes muscles to move. Excessive 
movement is often caused by excessive flexing of muscles. Nerve impulses cause acetylcholine 
to be produced and travel across the gaps between nerves. When it binds to the second nerve, it 
fires, eventually stimulating the prospective muscle. Anticholinergics prevent the acetylcholine 
from binding to the second nerve, thus limiting muscle stimulation. 
Common anticholinergic medications are:Benztropinemesylate, Carbidopa-levodopa, 
Glycopyrrolate, Procyclidine hydrochloride, Trihexyphenidyl hydrochloride 
 
02. Anticonvulsants 
Anticonvulsants are prescribed to reduce or prevent seizure activitythat may occur. They also 
stabilize mood. Anticonvulsants reduce, or depress, excessive stimulation to the brain without 
affecting respiration or causing drowsiness. Different drugs control different types of seizures.  
Common anticonvulsants include:Gabapentin, Lamotrigine, Oxcarbazepine, Topiramate, 
Zonisamide. 
 
A Comparative Study on the Neuro-protective Effects of DHA, Vitamin-E And Memantine in the 
Neonatal Rat model Of LPS Induced Cerebral Palsy. 
 
Department of Pharmacology Page 31 
 
03. Antidepressants 
Antidepressants are psychiatric medications with mood altering and analgesic qualities used to 
treat depression, anxiety, and in some cases seizures. One-third of those with a chronic illness, 
such as Cerebral Palsy, may be depressed. Depression is a persistent sense of sadness, 
helplessness, and hopelessness. 
In addition, depression can worsen the medical condition by: 
 Aggravating the Cerebral Palsy 
 Decreasing confidence 
 Increasing fatigue 
 Intensifying pain 
 Worsening ability to cope 
 
Treatment for depression is multi-faceted. Focus is on gaining emotional support, guidance, 
counseling, and perspective. Antidepressants can also be harmful during pregnancy. Drug 
therapy can be used exclusively or in combination with any of the following: 
 Behavioral therapy – to identify and address perception and gain new perspective 
 Biofeedback and massage therapy – to relax, meditate, calm, peacefully escape, and energize 
 Healthy diet and exercise – to provide the body with essentials to cope 
 Sleep – to rest properly and re-energize 
Side effects from antidepressants may include: 
 Agitations, blurred vision, constipation, dizziness, dry mouth, headache, insomnia, 
nausea, nervousness, stomach upset,  
Some commonly prescribed antidepressants include: 
 Citalopram, lexapro, Prozac, paxil, zoloff. 
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04. Anti-Spastic Drugs 
Antispastics, also known as muscles relaxers, are prescribed to relax contracted, overactive, or 
stiff muscles. Antispastic medications are often the first treatment choice for reducing tremors or 
controlling widespread spasticity. 
Oral medications are usually prescribed for overall spasticity, while injections target a specific 
muscle. The benefits of oral medications and injections are usually short-term, requiring refills or 
further injections.  
Alcohol wash injections target specific nerves and can provide relief for a few months to several 
years. Botox is usually administered in three-month intervals. Other injectable antispasmodics 
typically remain effective for about three to eight months. The intrathecal baclofen pump is 
found to be most effective on those with chronic, severe stiffness and those with uncontrolled 
muscle movements. 
Some benefits derived from antispastic medications include: 
 Control muscle contractions 
 Increase range of motion 
 Reduce tremors and muscle spasms 
 Relax overactive muscles 
 Relax tight muscles 
 
Possible side effects to anti-spastic medications may include: Confusion, constipation, diarrhea, 
dizziness, drowsiness, flu-like symptoms, headache, high blood pressure liver damage, slurred 
speech.  
Medications vary in the way they relax muscles. Some, like baclofen, relax the muscle directly, 
while others, like diazepam, act on brain chemistry. Botox (botulinium toxin) causes mild muscle 
paralysis. Commonly prescribed anti-spastic medications include: 
Botulinum toxin, or Botox, diazepam, dantrolene, tizanidine. 
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05. Anti-Inflammatory Drugs 
Medscape reports 67%-84% of individuals with Cerebral Palsy experience pain lasting one hour 
or longer per episode. Anti-inflammatory agents alleviatepain by reducing inflammation. 
Many medications and alternative treatments are available to manage pain often associated with 
Cerebral Palsy. Pain medication includes non-steroidal, anti-inflammatory drugs (NSAIDs) or 
anti-inflammatory corticosteroids. Many of these medications play a significant role in reducing 
pain as they alleviate the primary causes of discomfort. 
Pain can result from the actual health conditions involved with Cerebral Palsy, or can be 
experienced when exercising, strengthening and expanding range-of-motion during physical 
therapy.  
Some common origins of pain in those with Cerebral Palsy, include: 
 Gastrointestinal pain – abdominal pain related to digestive complications from malnutrition, 
malabsorption, impaired orofacial functioning, esophageal issues, aspiration, incontinence, 
constipation and flatulence. 
 Orthopedic pain – deformity, compensation, subluxation, degeneration, and dislocation found 
in the face, fingers, hands, arms, shoulders, back, spine, hips, pelvis, legs, ankles, feet or toes. 
Procedures performed on the bones, ligaments, joints, tendons, muscles, and nerves. Orthotic 
overuse, underuse, skin irritation, and rubbing can cause pain, as well. 
 Rehabilitative therapies – pain worsened by therapy sessions involving assisted stretching 
and range of motion exercises, including occupational, physical, speech and language 
therapy. 
 Surgical pain – pain derived from surgical procedure, post-operative healing, and needle 
injections such as blood draws, pain medication, and intravenous feeds. 
 
Pain medication can be helpful in reducing or alleviating pain. Four main categories of anti-
inflammatories include: 
 Aspirin – suppresses prostaglandins, regulates body temperature, and constricts blood. 
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 Corticosteroids – anti-inflammatory agent with a large number of other functions, such as 
glucose utilization, fat metabolism, and bone development. 
 Nonsteroidal anti-inflammatory drugs (NSAIDs) – a non-steroid substance which has 
analgesic, antipyretic, and platelet-producing capabilities to primarily treat mild to moderate 
pain, and fever. 
 Steroids – decrease inflammation and reduce immune system activity. 
 
06. Stool Softeners 
Constipation is common in children with Cerebral Palsy. The condition can be caused by 
medications, lack of activity, inadequate fluid intake, dietary complications, and difficulty in 
accessing bathrooms and labored breathing. 
The primary way to treat constipation is with a healthy diet rich in high-fiber foods. Laxatives, 
which can be very useful, come in several forms. Stool softeners help to maintain water content 
to prevent stool from becoming hard and painful. Various stimulants induce bowel contractions 
and move stool along the intestinal tract. 
 
2.8.2. CONVENTIONAL & COMPLEMENTARY TREATMENT [18] 
Conventional treatment methods involve systems, practices and products that have been 
researched, tested and approved by the medical community as acceptable forms of treatment. 
Complementary medicine, when used under doctor supervision, can be used as a complement to 
an existing treatment plan. Alternative medicine is a treatment method that is used to replace 
conventional medicine. 
 
Six forms of complementary and alternative medicine 
The field of complementary medicine and alternative medicine is divided into six categories. 
They are: 
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A. Biological-based therapies 
Biological-based alternative treatments use substances that are found in nature. Echinacea and 
fish oil with omega 3s are common biological based therapies. These include amino acid, 
animal-derived extracts, botanicals, fatty acides, minerals, prebiotics, probiotics, proteins and 
vitamins. 
B. Energy therapies 
Energy therapies involve manipulation of energy fields (electromagnetic fields and 
biofields/putative fields) by channeling energy fields from the practitioner to the client to affect 
health and well-being. Energy therapy techniques include magnet therapy, light therapy, healing 
touch and Reiki. 
 
C. Manipulative and body-based methods 
In manipulative and body-based methods, the body systems and structures (bones, joints, soft 
tissues, circulatory system and lymphatic systems) are manipulated beyond their passive range of 
motion and with appropriate use of force. This method is commonly part of chiropractic and 
osteopathic medicine. Methods in this category include massage therapy and spinal 
manipulation. 
Mind and body methods attempt to use the mind techniques to affect physical function and to 
promote health. The concept of using the mind to treat illness is an important approach used in 
traditional Chinese medicine, Ayurvedic medicine and referenced in moral and spiritual aspects 
of the healing process by Hippocrates, the father of Western medicine. Mind-body interventions 
include acupuncture, deep-breathing exercises, guided imagery, hypnotherapy, meditation, 
progressive relaxation, tai chi and yoga. 
 
D. Movement therapies 
Movement therapies use body movement control in promoting emotional, mental, physical and 
spiritual balance and well-being. There are a broad range of Eastern and Western movement 
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methods including Alexander Technique, Feldenkrais Method, Pilates, Rolfing Structural 
Integration and Trager Psychophysical Integration. 
 
E. Whole medical systems 
Whole medical systems are complete medical systems of theory and practice evolved in various 
cultures over time. They do not include Western medicine or conventional medicine. They 
instead include ancient whole medical systems such as Ayurvedic medicine and traditional 
Chinese medicine, as well as modern whole medical systems such as homeopathy and 
naturopathy. 
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3. ANIMAL MODELS FOR CERBRAL PALSY 
[19-21] 
 
Animal models are commonly used to investigate the various pathophysiological mechanisms 
underlying the development of diseases. A critical aspect for the modeling of CP is the timing of 
the brain insult as there are species differences in the timing of key brain maturation events. It 
has been reported that in rodents the period between embryonic day 17 and postnatal day 7-10 
replicates many features seen in the third trimester in humans. Animal models of CP have been 
developed in a variety of species including mice, rats, rabbits, sheep and non-human primates. 
The most commonly used models include, 
 
1) Models of hypo-perfusion or HI model 
2) Models using either infectious agents or bacterial products 
3) Excitotoxic insults. 
4) Models of stroke 
 
 
3.1. HYPOPERFUSION MODEL 
 In the Rice-Vannucci HI model, rats undergo unilateral ligation of the carotid artery 
followed by exposure to 8% oxygen hypoxic air. 
 Although these animals are used to study CP since the animals show brain damage, 
hypoxia/ischemia, inflammation and motor and cognitive deficits. 
 Many modifications of the HI model have been made to try to get a model that better 
recapitulates features of human CP.  
 Some of these modifications included varying the day of the animals used and the 
example of hypoxic conditions.  
 In the Rice-Vannucci model, there is extensive damage to the gray matter.  
 Another model reduced the hypoxic conditions to 6% oxygen in an attempt to produce 
less severe brain damage. 
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3.2. INDUCTION USING INFECTIOUS AGENTS 
 One of the models used in the study of CP is based on lipopolysaccharide (LPS) as brain 
inflammation-inducing agent.  
 This toxin is a potent inducer of inflammation and has different effects on cells of the 
immune system, as microglial cells.  
 This produces model of brain inflammation in rats based on the unilateral stereotaxic 
injection of LPS, which mimics the inflammatory reaction produced in brain diseases 
such as Parkinson’s, Alzheimer disease and CP. 
 For establishment of chronic neuroinflammation such as Parkinson’s disease (PD) potent 
inflammatory agent, lipopolysaccharide (LPS) is used in order to gain better 
understanding of immune-mediated events in PD.  
 However, the effect of intra-cerebral LPS on neuroinflammation and neurodegeneration 
and its impact on motor function has been less well studied.  
 
3.3. FETAL SHEEP MODEL 
 There are several larger animal models besides mice and rats that might be more 
applicable to humans.  
 Fetal sheep have shown to have advantages over rodent models. Repeated measurements 
can be performed in-utero and they exhibit similarities to the third trimester in humans 
that can be accurately replicated. 
 
3.4. RABBIT IN-VIVO UTERINE MODEL 
 In rabbits, in vivo uterine ischemia by inflation of an aortic balloon at a level proximal to 
uterine arteries resulted in hypertonia and neurobehavioral findings in rabbits mimicking 
those found in CP. 
 
3.5. PERINATAL ASPHYXIA MODEL 
 In pigtailed macaques CP was modeled using an acute perinatal asphyxia model. 
Occlusion of the umbilical cord for 12-18 minutes before birth induced hypoxic-ischemic 
A Comparative Study on the Neuro-protective Effects of DHA, Vitamin-E And Memantine in the 
Neonatal Rat model Of LPS Induced Cerebral Palsy. 
 
Department of Pharmacology Page 39 
 
conditions resulting in neurodevelopmental and long term physical and cognitive deficits 
associated with CP. 
 
3.6. RAT MODELS OF STROKE 
 Animal models of stroke show many features of CP and have been used to study the 
disease.  
 These models have reproduced the hypoxic-ischemic (HI) conditions, the apoptotic-
necrotic pattern of white and gray matter damage and the neuromotor impairments. 
 
These models are important to develop early treatments and to determine if there are factors that 
worsen the condition. Another way to try to replicate human CP is to introduce inflammatory 
agents in animal models since these agents play a role in brain injury. However, it has been 
found that only some aspects of the human condition are replicated by this approach. 
Additionally, these studies were performed at any early point in the gestation of the animal 
models and do not correlate with the timing of the development of CP. It has also been found in 
the animal models that gestational stress worsens the condition. 
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4. TREATMENT DRUGS UNDER STUDY 
 
Presently there is no systematic approach to totally prevent or cure CP but treatments have been 
developed that can help reduce itsimpact on the patient’s quality of life. As with many diseases 
with varied symptoms, it isbest that treatments are initiated early in the course of the 
disease.Despite various therapies available to alleviate symptoms of CP, there remains an unmet 
need for better preventive and earlytherapies for rescue. The following class of drugs was chosen 
to study on the treatment of cerebral palsy, 
 
 VITAMIN- E TOCOPHEROL  
 DHA – DOCOSA HEXANOIC ACID 
 MEMANTINE 
 
5. OXIDATIVE STRESS & VITAMIN-E 
[24-28]
 
Oxidative stress may result in neuroinflammation, which is a highly recognized part of cerebral 
ischemia as well as many neurodegenerative diseases including cerebral palsy, Parkinson's 
disease, Alzheimer's disease, and Amyotrophic Lateral Sclerosis. 
A target in neuroprotective treatments was to reduce the induced oxidative stress because of their 
role in causing neuron apoptosis. Oxidative stress can directly cause neuronal cell death or it can 
trigger a cascade of events that may result in protein misfolding, proteasomal malfunction, 
mitochondrial dysfunction, or glial cell activation. Further neurodegradation is caused as each of 
these events causes’ neuron cell apoptosis. Neuroprotectives acts by eliminating this oxidative 
stress, therefore further neurodegradation can be inhibited. In order to eliminate the oxidative 
stress Anti-oxidants were employed. 
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Fig. No. 05 Free radicals and Oxidative stress 
Antioxidants are the primary treatment used to control oxidative stress levels. Antioxidants work 
to eliminate reactive oxygen species, which are the prime cause of neurodegradation. The 
effectiveness of antioxidants in preventing further neurodegradation is not only disease 
dependent but can also depend on gender, ethnicity, and age. 
 
Dietary antioxidants protect neurons against a variety of experimental neurodegenerative 
conditions. Several natural components and vitamins have potential against a variety of oxidative 
stress-induced neurodegenerative diseases. 
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5.1. VITAMIN – E (Tocopherol ) 
Vitamin E is a group of fat-soluble compounds that contain antioxidant distinctive activities. 
Vitamin E exists in 8 chemical forms; alpha, beta, and delta-tocopherol  and alpha-, beta-, 
gamma-, and delta-tocotrienol. In general, Vitamin E is a fat-soluble antioxidant that prevents the 
production of ROS formed during the process of the oxidation of fat. Scientists are currently 
investigating whether vitamin E could help prevent or slow the chronic diseases associated with 
free radicals. 
Deficiency in vitamin E can cause nerve and muscle damage to the point of loss of feeling in 
arms and legs, muscle weakness, and vision problems. It can also result in a weakened immune 
system. 
 
Vitamin E has many important biological functions which include: 
1. Antioxidant. 
2. Enzymatic Activities 
3. Gene Expression 
4. Neurological Functions 
5. Cell Signaling 
6. Protects Lipids and Prevents Oxidation of Polyunsaturated Fatty Acids 
 
5.2. SOURCES 
 PLANT FOODS:  
Sunflower seeds, wheat germ, almonds, hazelnuts, peanuts, vegetable oils, dark green leafy 
vegetables, taro, sweet potato, pumpkin, avocado, kiwifruit, fortified ready-to-eat cereals, 
nutrition bars, margarines, peanut butter and beverages. 
 
 ANIMAL FOODS:  
Oily fish (sardines, salmon, herring, trout, mackerel), mollusks (abalone, conch, snails), 
shrimps. 
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5.3. FORMS OF VITAMIN-E 
Vitamin E can be classified into two types - Tocopherol s and Tocotrienols. Each of these forms 
is named with prefixes such as alpha, beta, gamma, and delta. Among these forms, α-Tocopherol  
is of biological and physiological importance.  
 
 α-Tocopherol  
Alpha Tocopherol  mainly serve as an antioxidant in humans. Other functions of alpha-
tocopherol  is to inhibit the activity of protein kinase C. Protein kinase C is an important 
molecule for cell-signaling. Alpha-tocopherol  also affects the activity of enzymes in 
immune and inflammatory cells. 
 γ-Tocopherol  
Gamma Tocopherol  is the most common form of Vitamin E in North American diet. 
However, its function is not as well-known as alpha tocopherol .It appears that alpha-
tocopherol  lowers gamma-tocopherol  levels 
 
5.4. MECHANISM OF ACTION 
 α - Tocopherol  exhibits significant inhibition of neurotoxicity induced by a non-specific 
protein kinase inhibitor.  
 This PK inhibitor is known to induce apoptosis in many types of cells including neurons. 
 It is also known that α-tocopherol  protects striatal neurons by the reduction of oxidative 
stress gradually by decreasing intracellular O2
−
 levels, and by inhibition of apoptosis. 
 α - Tocotrienol prevents glutamate-induced death of immature and mature primary 
cortical neurons.   Also it reduces the production of IL-1β, IL-8 and TNF-α by 
leukocytes. 
 It also protects the integrity of the membrane by inhibiting the lipid peroxidation. 
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Fig. No. 06 Vitamin – E in oxidative stress 
5.5. NEUROPROTECTIVE EFFECTS 
Vitamin- E is capable of participating in the reduction of oxidative stress in diabetic patients by 
its antioxidant activity.  
It is also known that the use of vitamin-E after ischemic injury not only triggered the oxidative 
injury of the muscle cells but also reduced the formation of edema. It has protective effects on 
the retina during retinal ischemia-reperfusion injury. Also patients receiving cisplatin 
chemotherapy with vitamin-Edecreased the incidence and severity of peripheral neurotoxicity. 
 It is most effective in Alzheimer's disease and has been shown to haveneuroprotection effects 
when treating ALS. A meta-analysis involving 135,967 participants showed there is a significant 
relationship between vitamin E dosage and all-cause mortality, with dosages equal to or greater 
than 400 IU per day showing an increase in all-cause mortality. However, there is a decrease in 
all-cause mortality at lower doses, optimum being 150 IU per day. Vitamin E is ineffective for 
neuroprotection in Parkinson's disease. 
It also protects the integrity of the membrane by inhibiting the lipid peroxidation. 
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6. DHA – AN ESSENTIAL FATTY ACID FOR THE BRAIN [29-32] 
 
DHA, an essential fatty acid for the central nervous system DHA is the major n-3 PUFA 
constituent in the neuronal membranes,  enhances synaptic activities in neuronal cells present in 
approximately 30-40% of the phospholipids of the gray matter of cerebral cortex and 
Its effects on neuronal lipid composition, neurochemical signaling and cerebrovascular 
pathobiology, docosahexaenoic acid (DHA) emerges it as a neuroprotective agent against 
cerebrovascular disease. 
 
 
Fig. No. 07 Mechanism of action of DHA 
Brain tissue has the highest concentration of DHA in the body, suggesting that brain function 
relies in unique ways on this powerful fatty acid. Within the brain itself, regions most closely 
related to memory show the greatest DHA concentrations. And even at the cellular level, DHA 
concentrates in the structures involved in forming new memories, such as synaptic membranes 
and tiny outgrowths called "neurites." 
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DHA resides almost exclusively in cell membranes, which undergo continuous degradation and 
renewal.That means in turn that the body needs a constant dietary supply of DHA to avoid 
depletion and neuronal injury.  
6.1. DIETARY INTAKE 
DHA can be obtained through diet or from α-linolenic acid. Other than diet neurons lack the 
enzymes necessary for de novo DHA and arachidonic acid synthesis, hence DHA gets  
synthesized from the dietary precursors, a- to a limited extent via conversion from its precursor, 
α-linolenic acid (α-LNA) linoleic acid in liver and in a minor way in cerebral endothelium from 
where they are exported to neuronal cells.  
DHA supplementation in humans at 2g/day provides sufficient DHA to maintain healthy 
function, but levels drop when the patients stopped taking the supplements. 
 
6.2. FUNCTIONS OF DHA 
DHA influences how the brain develops and functions, 
 It helps to determine brain structure, and it protects brain tissue from damage. 
 DHA's protective effects come from three distinct mechanisms: DHA protects brain 
tissue from inflammatory damage. It accomplishes this by promoting development of 
anti-inflammatory molecules while suppressing pro-inflammatory molecules in brain cell 
membranes. 
 DHA stimulates physical changes that underlie learning and memory. 
 DHA promotes outgrowth of neurites, the tiny projections that form intimate connections 
between cells as memories form. 
 DHA promotes rapid signal transduction across synapses and helps membranes maintain 
their fluidity, a condition required for rapid changes in shape and function we recognize 
as memory. 
 DHA promotes healing after injury to brain tissue. Immediately after such an injury, cell 
membranes release DHA in massive amounts for conversion into compounds called 
protectins. 
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 DHA is necessary to maintain proper physical conformation of ion channels, receptors 
and transporters in membranes in cells involved in memory, synaptic membrane 
biogenesis and function and neuroprotection . 
 Depletion of DHA induces extensive damage of sensory, behavioral and cognitive 
function 
 DHA improves behavioral function, decreases infarct volume, promotes cell survival in 
the ischemic penumbra as well as resolution of cerebral edema photoreceptor cells in the 
retina. 
 
6.3. REDUCED DHA LEVELS 
Reductions in perinatal brain DHA accrual are associated with deficits in neuronal arborisation, 
multiple indices of synaptic pathology including deficits in serotonin and mesocorticolimbic 
dopamine neurotransmission, neurocognitive deficits, elevated behavioral indices of anxiety, 
aggression and depression and decreased visual acuity. In primates and humans, preterm delivery 
has been shown to be associated with the same troubles which can be reverted by n-3 PUFA 
supplementation [9]. After the perinatal brain development, DHA intake remains essential for the 
normal maintenance of brain functions including synaptic plasticity, neurotransmission and 
vision. 
6.4. EFFECTS OF PERINATAL DHA 
In the last trimester of fetal life and the first two years of childhood, the brain undergoes a period 
of rapid growth termed the “brain growth spurt”. During this period, the need in this PUFA is 
dramatically elevated because of the increase in brain size and in relative DHA contents. The 
polyunsaturated fatty acid docosahexaenoic acid (DHA) has intrinsic neuroprotective properties 
and investigated for utilizing it as an oral supplement for pregnant women. 
 
Animal studies have demonstrated that reductions in perinatal brain DHA accrual are associated 
with deficits in neuronal arborisation, multiple indices of synaptic pathology including deficits in 
serotonin and mesocorticolimbic dopamine neurotransmission and neurocognitive deficits. In 
humans, preterm delivery is associated with disorders those which can be reverted by providing 
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DHA supplementation. DHA intake remains essential even after the complete brain development 
for the normal functioning of the brain that includes synaptic plasticity, neurotransmission and 
vision. 
 
7. EXCITOTOXICITY AND MEMANTINE 
[33-35] 
Glutamate excitotoxicity is one of the most important mechanisms known to trigger neuronal cell 
death in cerebral palsy. Excitotoxicity is involved in many types of acute and chronic CNS 
neurodegenerative disorders and is connected with Ca2+ overload. Disturbance of glutamate 
homeostasis probably plays a pivotal role in neuropathology triggered by other factors such as: 
energy deficits, free radicals formation, etc. that facilitate the neurotoxic potential of endogenous 
glutamate. 
Although glutamate is a crucial mediator of physiological communication between neuronal 
cells, under certain conditions activation of glutamate receptors kills neurones - a term called 
“excitotoxicity”. 
7.1. GLUTAMATE RECEPTORS  
Glutamate is the fast excitatory neurotransmitter in the mammalian CNS. It activates three major 
types of ionotropic receptors, namely c-amino-3- hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA), kainate and N-methyl-D-aspartate (NMDA) and several types of metabotropic 
receptors.  
AMPA receptors are probably involved in all forms of fast glutamatergic neurotransmission. All 
AMPA receptors are permeable to Na + and K + while complexes lacking GluR2 subunits are 
permeable to Ca 2+. NMDA-sensitive ionotropic glutamate receptors are permeable to Na +, K+, 
and Ca 2+. NMDA receptors are only activated following depolarisation of the postsynaptic 
membrane which physiologically follows AMPA receptor stimulation. This unique feature and 
the high Ca 2+ permeability renders NMDA receptors inherently suitable as mediators of 
synaptic plasticity (e.g. learning and memory). Uncompetitive NMDA receptor antagonist 
memantine block the NMDA channel in the open state.  
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FIG. NO. 08 GLUTAMATE RECEPTOR 
Glutamate is involved to some degree in virtually all CNS functions from primary sensory 
perception to cognition. The hippocampus is the structure most often connected with memory 
formation. All fast excitatory projection pathways to, within and from the hippocampus utilise 
glutamate as a transmitter. This brain region, due to its highly organised structure, is ideally 
suited for studies on long term potentiation (LTP) which is believed to represent an elementary 
feature of memory formation at the neuronal level. LTP refers to a persistent increase in synaptic 
sensitivity following high frequency stimulation of input neurones. NMDA receptors are 
involved in mediating the postsynaptic components of LTP in the hippocampus e.g. in the 
Schaffer collateral projection. 
 
 
 
 
A Comparative Study on the Neuro-protective Effects of DHA, Vitamin-E And Memantine in the 
Neonatal Rat model Of LPS Induced Cerebral Palsy. 
 
Department of Pharmacology Page 50 
 
7.2. PATHOGENESIS 
The neurotransmitter glutamateactivates several classes of metabotropic receptor and three major 
types of ionotropic receptor — α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), 
kinates and N-methyl-d-aspartate (NMDA). 
Over-excitation of NMDA (Glutamate) receptors, results in an increase in calcium ion (Ca
2+
) 
influx due to the lack of specificity in the ion channel opened upon glutamate binding. As 
Ca
2+
 accumulates in the neuron, the buffering levels of mitochondrial Ca
2+
 sequestration are 
exceeded, which has major consequences for the neuron. Because Ca
2+
 is a secondary messenger 
and regulates a large number of downstream processes, accumulation of Ca
2+
 causes improper 
regulation of these processes, eventually leading to cell death. Ca
2+
 is also thought to trigger 
neuroinflammation, a key component in all CNS disorders. 
 
Fig. No. 09 Excitotoxicity & Neuronal Death 
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7.3. GLUTAMATE ANTAGONISTS  
Glutamate antagonists are the primary treatment used to prevent or control excitotoxicity. The 
goal of these antagonists is to inhibit the binding of glutamate to NMDA receptors such that 
accumulation of Ca
2+
 and therefore excitotoxicity can be avoided. 
Memantine is a moderate affinity, uncompetitive NMDA receptor antagonist with strong voltage-
dependency and fast kinetics.The mechanism of action (MOA) of memantine is to provide both 
neuroprotection and reverse deficits in learning/memory by the same MOA. 
 
7.4. MECHANISM OF ACTION 
Memantine'sneuroprotective effect also increases brain levels of the neuronal marker, N-acetyl 
aspartate (NAA). Because NAA is found primarily on neuronal axons in the brain, hence the 
neuroprotective effect of memantine can be measured by quantifying the change in NAA 
concentrations in brain tissue. 
 
 
Fig. No. 10 MOA of Glutamate receptor  
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Memantine can interact with a variety of ligand gated ion channels. However, NMDA receptors 
appear to be a key target of memantine at therapeutic concentrations. Memantine is an 
uncompetitive (channel blocking) NMDA receptor antagonist. Memantine at high concentrations 
can inhibit mechanisms of synaptic plasticity that are responsible learning and memory. At lower 
concentrations memantine promotes synaptic plasticity and preserve or enhance memory. In 
addition, memantine can protect against the excitotoxic destruction of cholinergic neurons.  
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8. LITERATURE REVIEW FOR CEREBRAL PALSY 
 
1. Establishing a rat model of spastic cerebral palsy by targeted ethanol injection 
Yadong Yu et al., reported that ethanol as a chemical ablation agent specifically and thoroughly 
damages the pyramidal tract, and therefore, the animals display flexion spasms, which are a 
typical symptom of the cerebral palsy. 
Neural regeneration research, 2013; 8(34): 3255-3262. 
 
2. Animal Models and Treatments for Cerebral Palsy 
Fran norflus et al., reported the therapies available to alleviate symptoms of cerebral palsy that 
remains as an unmet need for better preventive and early rescue therapies. Also discussed about 
the animal models that are being developed that mimic some aspects of the disease. Small animal 
models are best at reproducing the molecular events and large animals might be closer 
anatomically to model the human form of the disease. 
SciMedCentral, 2016; 1(1): 1008. 
 
3. Rodent Hypoxia–ischemia Models for Cerebral Palsy Research: A Systematic Review 
Prakasham Rumajogee et al., compared and discussed the advantages, limitations, and the 
translational value for Cerebral palsy research of HI models of perinatal brain injury. 
Frontiers in Neurology, 2016; 7: 57. 
 
4. Animal Models of Cerebral Palsy: Hypoxic Brain Injury in the Newborn. 
Wilsonet al., reported the Hypoxic insults that are implicated in the spectrum of fetal disorders, 
including cerebral palsy (CP). In view of the major contribution of intrapartum risk factorsand 
prematurity to subsequent neurological morbidity and mortality in humans, it aimed to clarify the 
pathophysiology of brain injury, especially periventricular white matter damage (WMD), that 
occur in utero to the immature and near-term fetal CNS. 
Iran J Child Neurol. 2015; 9(2): 9–16. 
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5. Treadmill exercise improves motor and memory functions in cerebral palsy rats through 
activation of PI3K-Akt pathway 
Sun-Young Jung et al., evaluated the effects of treadmill exercise on motor and memory 
functions in relation with phosphatidylinositol 3-kinase (PI3K)-Akt pathway using CP rat model. 
Memory functions improvements were evaluated using Rota-rod test, step-down avoidance task, 
5-bromo-2’-deoxyuridine (BrdU) immunohistochemistry, and western blot for synapsin I, 
postsynaptic density-95 (PSD-95), PI3K, Akt, and glycogen synthase kinase-3β (GSK-3β). 
Journal of Exercise Rehabilitation 2017; 13(2): 136-142. 
 
6. Erythropoietin Attenuates Lipopolysaccharide-Induced White Matter Injury in the 
Neonatal Rat Brain 
Kumral et. al., demonstrated that a protective effect of EPO on LPS-induced WM injury in the 
developing brain. Regarding the wide use of EPO in premature newborns, this agent may be 
potentially beneficial in treating LPS-induced brain injury in the perinatal period. 
Neonatology. 2007; 92(4): 269-78. 
7. IGF-1 Can Either Protect Against or Increase LPS-Induced Damage in the 
Developing Rat Brain 
Yi pang et. al., tested whether IGF-1 can prevent PVL-like brain damage induced by 
lipopolysaccharide (LPS) in the neonatal rat. Intraventricular delivery of LPS resulted in an 
acute brain inflammatory response, i.e., rapid recruitment of polymorphonuclear leukocytes 
(PMNs), activation of microglia and astrocytes, and induction of IL-1β (IL1β) expression. 
Brain inflammation was associated with the loss of O4+ preoligodendrocytes (preOLs), a 
decrease of myelin basic protein (MBP) in the white matter and an increase of pyknotic cells in 
the cortex. IGF-1 at a low dose significantly prevented LPS-induced deleterious effects without 
alteration of IL-1β expression and microglia/astrocytes activation.  
Pediatr. Res. 2010 Jun; 67(6): 579–584. 
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9. SCOPE OF WORK 
 
Cerebral palsy is the most common childhood physical disability. There is no known cure for 
cerebral palsy, but fortunately there are many treatments that can help both children and adults 
with cerebral palsy.  
Premature delivery may result in the brain damage of the new born, and causes impairments such 
as loss of senses and permanent cognitive impairment. Early treatment for children with cerebral 
palsy is important because the developing brain and the body are more resilient. Multi-
disciplinary team is operational in treating cerebral palsy, which involves localized treatment 
specific for the particular symptoms. 
 
The scope of this work is to bring up the treatment regimen that prevents the fetus being affected 
by the maternal antibodies; there is currently only symptomatic relief. But currently some 
category of drugs like stimulants and non-stimulants were used along with some antioxidants and 
some other supportive therapy. Therefore there is a lot of promising scope in the development of 
drug therapy for this chronic and debilitating disorder.  
 
The present study is carried out in order to prevent the neuro-degrading conditions that need to 
be avoided during the gestation period. Treating cerebral palsy after the initiation of neuro-
degeneration of the nervous system will not fetch any results as this complete process is 
irreversible and can never be cured completely. Hence, prenatal treatment with energy-rich 
neuronal supplementation will be the choice for preventing CP and for brain development 
. 
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10. PLAN OF WORK 
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11. MATERIALS AND METHODS 
 
11.1. EXPERIMENTAL ANIMALS: 
All experimental protocols were approved by the Committee for the Purpose of Control and 
Supervision of Experiments on Animals (CPCSEA) and Institutional Animal Ethical Committee 
(IAEC). 
 
11.2. ANIMAL SELECTION   
Female Sprague dawley rats weighing 200 – 270 g of around 8-9 weeks of age were used for this 
study. Male SD rats will reach sexual maturity at approximately 10-12 weeks of age, although 
females may have their first estrus as early as 8-9 weeks of age. The animals were procured from 
the animal house of King Institute of Preventive Medicine and Research is a medicine research 
institute located in Guindy, Chennai. 
 
11.3. ANIMAL HUSBANDRY 
They were housed six per cage under standard laboratory conditions at a temperature 22±2°C 
with 12:12 hrs light and dark circle. Rats were housed in the ratio of 3 females for 1 male in 
standard polypropylene cages (size: approximately L 410 x B 280 x H 140 mm), with stainless 
steel top grill having facilities for pellet food and drinking water in glass bottle. The animals 
were provided with standard animal feed, water and ad libitum. The animals were adapted to 
laboratory conditions one week prior to initiation of experiments. All experiments were carried 
out according to the guidelines for care and use of experimental animals and approved by 
Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). 
The study was approved by Institutional Animal Ethical Committee (IAEC). 
 
11.4. MATING OF RATS 
[36, 37] 
The duration of the estrous cycle of rats is 4–5 days, it is on these days mating occurs. Mating is 
usually nocturnal. One male and up to three females are housed together for mating. In order to 
confirm pregnancy, vaginal smears must be taken at the same time each day, preferably in the 
morning, for a minimum of 7 consecutive days. 
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11.4.1. EXAMINATION OF THE MORPHOLOGY OF VAGINAL SMEARS 
Vaginal smears must be taken at the same time each day, preferably in the morning, for a 
minimum of 7 consecutive days.  
Wet smears:   
 Lift the female by the base of her tail 
 Use a blunt-tipped disposable pipette to flush then aspirate approximately 0.2 ml of 
saline into the vaginal cavity, repeat 2 times. Place fluid onto a clean microscope slide 
and cover using a cover slip.  
 
11.4.2. EXAMINE SMEARS UNDER A MICROSCOPE AT LOW POWER 
 Proestrus: lasts approximately 12 hours and has abundant nucleated non-cornified 
epithelial cells.   
 Estrus: lasts up to 12 hours and is indicated by the presence of large cornified cells in the 
vaginal smear.   
 Metestrus: lasts approximately 21 hours and usually has many neutrophils in the smear 
and scattered squamous epithelial cells.  
 Diestrus: lasts up to 57 hours and there are abundant neutrophils and a few nucleated 
non-cornified epithelial cells. 
 
11.5. EXPERIMENTAL DESIGN: 
 
10.5.1. INTRODUCTION: 
According to Catherine Rousset., et. Al., cerebral palsy in the neonates can be induced using 
lipopolysaccharide injected intraperitoneally to the pregnant S.D rats.  
 
11.5.2. PROCEDURE: 
 
 Sprague dawley rats were allowed to mate at 22±1ºc under a 12 hour light and 12 hour 
dark cycle. They were provided free access to food and water ad libitum. 
 After confirming pregnancy by vaginal smear test, drug treatment is initiated for the 
respective treatment arms. 
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 From Day 5 of gestation period, treatment is initiated with DHA, Memantine and 
Tocopherol  for Groups C, D and E respectively.  
  Doses of drugs are as below: 
 DHA - 2.5mg/kg 
 Memantine - 20 mg/kg 
 α- tocopherol  - 150mg/day 
 Treatment is followed till 20th day of Gestation. On 19th dayof gestation LPS 500 µg/kg 
i.p. was administered. 
 Once the pups were born, they follow weaning period of up to 21 to 23 days. After which 
they are separated for analyzing their motor, sensory and cognitive functions.  
 
11.5.3. TREATMENT GROUPS 
Table 01: Grouping of Animals 
GROUP TREATMENT REGIME ANIMALS 
Group A Control 3 Female SD  rats 
Group B 
Negative control – LPS induced Periventricular leukomalacia 
(PVL) 
3 Female SD  rats 
Group C – DHA 
LPS induced PVL and treated with intraperitoneal injections of 
DHA at 2.5mg/kg 
3 Female SD  rats 
Group D – 
Memantine 
LPS induced PVL and treated with intraperitoneal injections of 
Memantine 20 mg/kg 
3 Female SD  rats 
Group E – α–
Tocopherol  
LPS induced PVL and treated with intraperitoneal injections of 
150mg/day α- tocopherol . 
3 Female SD  rats 
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12. METHODS OF ASSESSMENT (in-vitro) 
All the parameters were assessed on Day 21 of the newborn rat pups. 
12.1. ASSESSMENT OF MOTOR ACTIVITY 
12.1.1. Actophotometer test 
1. Spontaneous locomotor activity of each group of the pups was measured using 
actophotometer with infrared sensitive photocells.  
2. Before locomotor test, each animals were placed individually in the actophotometer cage 
for 2 min for habituation.  
3. Thereafter, locomotor activity was recorded for a period of 5 min for pups from group A, 
B, C, D and E.  
4. During this period, locomotor activity and immobility time were recorded in secs.  
5. The difference in the activity was recorded considering control Group A and after 
treatment groups i.e. B, C, D and E.  
6. Finally percentage decrease in locomotor activity was calculated at the 21st day of birth. 
12.1.2. Wire Hang test 
1. The Wire Hang test is used to evaluate motor function and deficit in rodent models of 
CNS disorders. It detects neuroprotective effects of different treatments at early and late 
time points (up to 3 weeks) in 30- and 60-minute transient MCAo.( Middle cerebral 
artery occlusion 
2. The test begins with the animal hanging from an elevated wire cage top.  
3. The distance of 37 cm is sufficient to encourage mice to remain hanging, but also low 
enough to prevent mice from injuries when falling down.  
4. The animal from each group is placed on the cage top, which is then inverted and 
suspended above the home cage.  
5. When the rat falls off the wire, timer is stopped and the hanging time is recorded. When 
rats are able to hang for 600 sec, they are returned to the respective cages.  
6. Rat pups that fall before this limit are given a maximum of two more tries. Maximum 
hanging time (i.e. the longest of the trials) is recorded for each group of rat pups. 
7. The average performance is presented as the average of the three trials. 
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8. Total 5 groups were involved and their average hanging time was concluded using 
MEAN±SEM. 
9. Motor activity was assessed on day 21. 
12.1.3. Rotarod Test 
1. Motor coordination and balance was assessed using a rotarod apparatus.  
2. In total, four training trials per day with an interval trial time of one hour were performed. 
Rats falling off during a training trial were put back on the rotating rod. Following the 
training days, a one day test of three trials was performed using two speed levels (10 & 
20 R.P.M) mode of the apparatus over 5-min.  
3. Animals are placed individually in separate lanes on rod rotating at 5rpm such that 
animals may walk forward to keep balance. 
4. The rotating rod is allowed to rotate at 10 rpm and animals from each group are placed 
individually on the rod and the fall off time was recorded for each animal. 
5. Similar procedure is followed by increasing the speed to 20 rpm. 
6. Total 5 groups were involved and their average hanging duration was concluded using 
MEAN±SEM. 
7. Skeletal muscle activity was assessed on day 21. 
12.2. ASSESMENT OF SENSORY MOTOR ACTIVITY 
12.2.1. Cliff-drop aversion: 
Cliff aversion tests the labyrinth reflexes, as well as strength and coordination and can be used to 
test pups from neuro-developmental disorder.  
A pre-scented box with a flat elevated ledge is used and the pup is placed with the digits only of 
their forepaws and their snout positioned over the edge. Scoring is performed by counting the 
total time it takes the pup to turn away from the cliff and move its paws and snout away from the 
edge. If no response is seen after 30 sec, the test is terminated.  
Pups are placed on the edge of the box, making sure that the forepaws, digits and snout are the 
only parts over the edge. 
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1. The pup is released and timer is started. 
2. Each pup is placed on the edge of a cliff with the forelimbs partially on and partially off 
this surface.  
3. The mature response is that the animal quickly turns its head and forelimbs and avoids 
dropping. This test allows us the evaluate the somatosensory function. 
4. Once both the snout and paws have been removed from the edge, the timer and record 
time is stopped 
5. Similar procedure is repeated for pups in Group B, C, D and E. 
8. Total 5 groups were involved and their average head turn, arm turn and complete 
avoidance rate was concluded using MEAN±SEM. 
6. Sensory motor activity was assessed on day 21 
12.2.2. Adhesive Removal Test 
1. The test rats are restrained and using a pair of small forceps one adhesive label is placed 
onto the snout of the rats.  
2. The label is pressed on the snout with the forceps and released. And the lid is placed on 
the cage and time is noted.  
3. The time when the rat pup attempts to remove the label with its forepaws is recorded. If 
the animal makes contact but does not remove the label,time is extended until it removes 
it. 
4. Contact time and time of removal of the adhesive is noted for all the Groups. 
5. If the rat does not contact or remove the sticker within 60 sec then the trial is ended and 
the sticker is removed manually. 
6. After completion, the animal is placed back in the clean cage and next ratfrom another 
group is tested.  
7. Total 5 groups were involved and their average time of adhesive removal was concluded 
using MEAN ± SEM. 
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12.3. ASSESMENT OF MEMORY AND LEARNING 
12.3.1. Spatial Memory Performance in Water Maze Probe Trial 
 The spatial learning and memory test was performed by the method of Morris water-
maze.. 
 Water maze test was consisted of a place navigation test and a probe test. The place 
navigation test was performed as two trials daily for 5 consecutive days.  
 Rats were trained to locate and escape onto the platform during the training session.  
 A different starting position for each rat was used in each trial. 
 The pups were allowed to swim freely to find the hidden platform within 60 s.  
 Animals that are failed to find the location within the given time were guided to the 
platform and were allowed to stay on it for 20 to 40 sec and then returned to the cage.  
 For each individual treatment group, the position of the platform was fixed throughout 
the test.  
 The escape latency and platform crosses of each rat per day were calculated.  
 On the memory retention session (probe test), a single test was conducted in which the 
platform was removed.  
 Total 5 groups were involved and their average time in target platform was concluded 
using MEAN ± SEM 
 Cognitive function is analyzed on 21st day of rat pups. 
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13. STATISTICAL ANALYSIS: 
 
Data are reported as mean ± SEM and subjected to one-way analysis of variance (ANOVA). The 
statistical analysis was carried by one way ANOVA followed by Dunnett’s test.  
The P value< 0.05 (95% confidence limit) was considered statistically significant.  
Statistical analysis were done using Software Graph pad Prism 6.0.  
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13.1. Effect of DHA, Tocopherol and Memantine In Neonatal Rats Using Actophotometer 
S.NO GROUP PHOTOCELL COUNTS (5 MINS) 
01 Control 210 ± 13.34 
02 Negative control 45 ± 6.13 
03 DHA 194 ± 5.26
A*B***
 
04 Tocopherol  172 ± 14.10
 A*B**** 
05 Memantine 178 ± 16.11
 A*B**** 
 
Table 01:  Effect of DHA, Tocopherol  and Memantine In Neonatal Rats Using Actophotometer 
 
Values are presented as mean ± SEM, (n=5). Comparison:  Group II vs. Group III, IV, V. 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s‘t’ test. (ns- Non significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) 
 
 
Graph 01: Actophotometer – Locometer activity 
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13.2. EFFECT OF DHA, TOCOPHEROL  AND MEMANTINE IN NEONATAL RATS 
USING ROTAROD TEST 
 
S.NO GROUP Fall off latency (10 RPM) Fall off Latency (20 RPM) 
01 Control 82 ± 4.42 65 ± 7.6 
02 Negative control 18 ± 2.08 17 ± 4.12 
03 DHA 79 ± 4.3 43 ± 11.5 
04 Tocopherol  85 ± 2.40 48 ± 2.64 
05 Memantine 74 ± 1.69 35 ± 6.25 
 
Table 02:  Effect of DHA, Tocopherol and Memantine In Neonatal Rats Using Rota-rod test 
 
Values are presented as mean ± SEM, (n=5). Comparison: Group II vs. Group III, IV,V 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s‘t’ test. (ns- Non significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) 
 
 
Graph 02: Rota-rod test 
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13.3. EFFECT OF DHA, TOCOPHEROL AND MEMANTINE IN NEONATAL RATS 
USING CLIFF-DROP AVOIDANCE TEST 
S.NO. GROUPS HEAD TURN ARM TURN 
COMPLETE 
AVOIDANCE 
01 Control 98 ± 3.06 100 ± 1.84 51 ± 1.49 
02 Negative control 39 ± 0.91 45 ± 3.56 18 ±1.31 
03 DHA 90 ± 1.04 83 ± 1.19 39 ± 2.25 
04 Tocopherol  96 ± 2.25 90 ± 2.71 41 ± 3.02 
05 Memantine 80 ± 1.67 85± 2.48 44 ± 1.10 
 
Table 03:  Effect of DHA, Tocopherol and Memantine In Neonatal Rats Using Cliff-drop avoidance test 
 
Values are presented as mean ± SEM, (n=5). Comparison:  Group II vs. Group III, IV, V. 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s‘t’ test. (ns- Non significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) 
 
 
Graph 03: Cliff-drop Avoidance test 
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13.4. EFFECT OF DHA, TOCOPHEROL AND MEMANTINE IN NEONATAL RATS 
USING WIRE HANG TEST 
 
S.NO GROUP HANGING DURATION (secs) 
01 Control 28 ± 1.5 
02 Negative control 9 ± 0.88 
03 DHA 24 ± 1.52 
04 Tocopherol  18 ± 0.577 
05 Memantine 18 ± 1.15 
 
Table 04:  Effect of DHA, Tocopherol and Memantine In Neonatal Rats Using wire-hang test 
 
Values are presented as mean ± SEM, (n=5). Comparison: Group II vs. Group III, IV, V. 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s‘t’ test. (ns- Non significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) 
 
 
 
Graph 04: Hanging wire test 
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13.5. EFFECT OF DHA, TOCOPHEROL AND MEMANTINE IN NEONATAL RATS 
USING ADHESIVE REMOVAL TEST 
 
S.NO GROUP Contact time (secs) Removal time (secs) 
01 Control 15 ± 2.51 20 ± 8.23 
02 Negative control 38 ± 2.36 60 ± 4.03 
03 DHA 21 ± 0.24 29 ± 0.57 
04 Tocopherol  25 ± 4.20 31 ± 3.43 
05 Memantine 18 ± 3.18 28 ± 2.56 
 
Table 05:  Effect of DHA, Tocopherol and Memantine In Neonatal Rats Using Adhesive removal test 
 
Values are presented as mean ± SEM, (n=5). Comparison: Group II vs. Group III, IV, V. 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s‘t’ test. (ns- Non significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) 
 
 
Graph 05: Adhesive Removal test 
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13.6. EFFECT OF DHA, TOCOPHEROL AND MEMANTINE IN NEONATAL RATS 
USING SPATIAL LEARNING TEST 
S.NO GROUP 
TIME IN TARGET 
QUADRANT (%) 
ESCAPE LATENCY 
01 Control 29.2 ± 1.36 31±7.21 
02 Negative control 24.6 ± 2.3 48±5.21 
03 DHA 30.1 ± 4.32 28±4.47 
04 Tocopherol  29.5 ± 2.6 34±3.35 
05 Memantine 28.1 ± 3.16 36±5.12 
 
Table 06:  Effect of DHA, Tocopherol and Memantine In Neonatal Rats Using Spatial learning test 
 
Values are presented as mean ± SEM, (n=5). Comparison: Group II vs. Group III, IV, V.  
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s‘t’ test. (ns- Non significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) 
 
Graph 06: Morris Water-maze test 
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13.7. EFFECT OF DHA, TOCOPHEROL AND MEMANTINE IN INDUCING TNF - α 
S.NO GROUP TNF – α (pg/ml) 
01 Control                                34.9 ± 8 
02 Negative control 50.4 ± 10.1 
03 DHA 33.3 ± 4.3
** 
04 Tocopherol  40.12 ± 5.2
***
 
05 Memantine 34.32 ± 6.2
**
 
 
Table 07:  Effect of DHA, Tocopherol and Memantine In Inducing TNF - α 
 
Values are presented as mean ± SEM, (n=5). Comparison:  Group II vs. Group III, IV, V.  
Statistical significance test for comparison was done by one way ANOVA followed by Dunnet’s 
‘t’ test. (ns- Non significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) 
 
Graph 07: Estimation of TNF α 
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13.8. EFFECT OF DHA, TOCOPHEROL AND MEMANTINE IN INDUCING IL-6 
S.NO GROUP INTERLEUKIN – 6 (pg/ml) 
01 Control 120.23 ± 12.1 
02 Negative control 190.17 ± 9.23 
03 DHA 140.23 ± 5.36 
** 
04 Tocopherol  146 ± 3.63
** 
05 Memantine 173.36 ± 12
*** 
 
Table 08:  Effect of DHA, Tocopherol and Memantine In Inducing IL-6 
 
Values are presented as mean ± SEM, (n=5) Comparison:  Group II vs. Group III, IV, V. 
Statistical significance test for comparison was done by one way ANOVA followed by 
Dunnet’s‘t’ test. (ns- Non significant, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001) 
 
 
Graph 08: Estimation of IL-6 
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14. RESULTS 
14.1. INDUCTION OF PVL 
Periventricular Leukomalacia, which is known to cause cerebral palsy, was induced in the 
pregnant rats at the Gestation day of 19. It was successfully induced by intraperitoneal injection 
of LPS (Bacterial product) 500 µg/kg of the G-19 female rats. Abrupt rise in TNF-α and 
Interleukin – 6 after 4 hours of LPS administration confirms the inflammatory response induced 
in the brain. 
 
14.2. ASSESMENT OF MOTOR ACTIVITY 
14.2.1. Effect of DHA, Tocopherol  and Memantine in neonatal rats using Actophotometer 
 The Group II animals showed significant decrease in locomotor activity when 
compared with Group I animals.  
 Treatment with DHA, Tocopherol  and Memantine showed significant increase in 
(p<0.001, p<0.01, p<0.001 for Group III, IV, V respectively) locomotor activity when 
compared with group II.  
 
14.2.2. Effect of DHA, Tocopherol  and Memantine in neonatal rats using Rota-rod 
apparatus 
 The fall off time of Group II animals has decreased when compared withGroup I animals. 
 Treatment with DHA, Tocopherol  and Memantine showed significant increase (p<0.01, 
p<0.01, p<0.01 for Group III, IV, V respectively) in fall off timewhen compared with 
Group II animals. 
 
14.2.3. Effect of DHA, Tocopherol  and Memantine in neonatal rats using Hanging wire test 
 The hanging duration of Group II animals was remarkably decreased when compared 
withGroup I animals. 
  Treatment with DHA, Tocopherol  and Memantine showed significant increase in 
hanging duration (p<0.001, p<0.01, p<0.01 for Group III, IV, V respectively) when 
compared with Group II animals.  
  
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14.3. ASSESMENT OF SENSORIMOTOR ACTIVITY 
14.3.1. Effect of DHA, Tocopherol  and Memantine in neonatal rats using Cliff-Drop 
aversion test 
 The Group II animals showed significant decrease in the number of head turns and body 
turns when compared with Group I animals. 
 Complete avoidance of the Group II animal when being placed at the cliff also seems to 
be less when compared with Group I. 
 Treatment with DHA, Tocopherol  and Memantine showed significant increase in 
(p<0.001, p<0.0001, p<0.001 for Group III, IV, V respectively) locomotor activity when 
compared with group II.  
 
14.3.2. Effect of DHA, Tocopherol  and Memantine in neonatal rats using Adhesive 
Removal test 
 The Group II animals showed significant increase in the time taken to remove the 
adhesive when compared with Group I animals.  
 Time taken to sense and contact the adhesive is found to be more in Group II when 
compared with Group I. 
 Treatment with DHA, Tocopherol  and Memantine showed significant decrease in 
latency to remove the adhesive ( p<0.01, p<0.001, p<0.01 for Group III, IV, V 
respectively) when compared with group II.  
 
14.4. ASSESMENT OF COGNITION AND LEARNING 
 
14.4.1. Effect of DHA, Tocopherol  and Memantine in neonatal rats using Morris-water 
maze test 
 The Group II animals showed significant increase in the time taken to escape and reach 
the target quadrant when compared with Group I animals.  
 Time spent in the target quadrant is found to be less in Group II when compared with 
Group I. 
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 Treatment with DHA, Tocopherol  and Memantine showed significant increase in the 
time spent in the target quadrant ( p<0.0001, p<0.001, p<0.0001 for Group III, IV, V 
respectively) when compared with group II.  
 
14.5. ESTIMATION OF TNF α & INTERLEUKIN  
Expression of tumor necrosis factor-α and interleukin-6 was observed more frequently in brain 
lesions with periventricular leukomalacia. TNF α is known to be responsible for the neuronal 
pain in most of the degenerative conditions. Hence it was found that, increase in the measure of 
TNF α & Interleukin 6 is the marker of cerebral palsy. Pro-inflammatory cytokines plays a major 
role in the development of PVL.  
Estimation of TNF α and IL-6 was carried out using ELISA type assay. 
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15. DISCUSSION 
 
Brain injury induced remains a major cause of cerebral palsy. Although therapeutic hypothermia 
is now established to improve recovery from hypoxia–ischemia (HI) at term, many infants 
continue to survive with disability, and hypothermia has not yet been tested in preterm infants. 
There is increasing evidence from in vitro and in vivo preclinical studies that stem/progenitor 
cells may have multiple beneficial effects on outcome after hypoxic–ischemic injury. 
Stem/progenitor cells have shown great promise in animal studies in decreasing neurological 
impairment; however, the mechanisms of action of stem cells, and the optimal type, dose, and 
method of administration remain surprisingly unclear. 
In this study we investigated the underlining cellular mechanisms responsible for the 
neuroprotective effects of DHA, Vitamin-E and Memantine treatment in prenatal white matter 
injury in the developing rat brain. We have demonstrated the behavioral phenomena by means of 
in-vitro tests that are being carried out in the neonatal CP induced rats. 
 
As per existing studies, neuroprotective effects were limited to TG-enriched only in DHA, but 
not EPA. Also, neuroprotection was evident when n-3 TG were injected 2 hr after the H/I injury. 
The present study has revealed the ameliorative effect of DHA, Memantine and Tocopherol  on 
LPS-induced cerebral palsy in SD neonates.  
 
LPS induced sensory motor and memory impairments was assessed by using various behavioral 
parameters like Rota-rod apparatus and Morris water maze test. It was found that treatment with 
DHA and Tocopherol  protects the cognitive deficits of the neonatal rats. 
 
Locomotor activity was assessed using Actophotometer based on locomotion in closed field and 
treatment with DHA, Tocopherol  and Memantine reported that the increase in the locomoter 
activity when compared to –ve control group which exhibited considerably lesser locomoter 
count and time spent duration in the Rota-rod.  
. 
Skeletal muscle activity was assessed by rota-rod apparatus. LPS induced PVL animals showed 
high fall off time in rota-rod apparatus. Treatment with DHA, Tocopherol  and Memantine in 
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deficit groups greatly reduced fall off time. This indicated that DHA and Tocopherol  has muscle 
relaxant property. 
 
Morris water maze task represents more specific for spatial memory. The essential feature of this 
technique is that rats are placed into large circular pool of water and can escape into a hidden 
platform. Thus, the platform offers no local cues to guide escape behavior and the rat can escape 
from swimming by climbing on to the platform apparently learns the spatial location of the 
platform any starting position at the circumference of the pool. The only spatial cues are those 
outside water tank are primarily visual cues. Thus, the versatility of the task makes it a widely 
acceptable experimental model for the assessment of cognitive tests. 
 
Typically, LPS induced animals exhibited an increase time for escape latency indicating loss of 
visual cues to escape to the platform. Such a diminished cognition was reversed by the 
administration of the DHA, Tocopherol  and Memantine at the specified dosage levels and 
exhibited escape latency (EL), indicating the well-developed spatial memory. 
 
Sensorimotor tests are carried out to determine the active sensory perception by the LPS induced 
PVL neonatal rats. These includes Cliff drop aversion test and adhesive removal test, which 
determines the sensory and motor activity of the CP induced animals. The active avoidance by 
DHA, Tocopherol  and Memantine Group in the cliff drop aversion test indicates better sensory 
and motor actions.  
 
Comparatively, prenatal treatment with DHA, an N-3 fatty acid rich triglycerides found to be 
more promising in ameliorating the effects of brain damage induced by LPS. DHA administered 
group experienced normal functioning in terms of locomotor, sensory and cognitive functions. 
Vitamin-E or Tocopherol  also exhibited effects similar to DHA but to lesser extent in terms of 
cognitive functions. 
NMDA receptor blockade with memantine provided an effective pharmacological prevention of 
PVL in the premature neonates, by protecting the degradation of  myelin sheath and lowering the 
effects of white mater damage on the neuronal development in the neonatal pups. 
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16. CONCLUSION 
 
In conclusion, the derived results demonstrate that DHA, TOCOPHEROL  and MEMANTINE 
could protect neuronal cells, and thereby preventing brain damage in adverse conditions. The 
neuroprotective pathway appears to implicate NMDA receptors and inflammatory modulation, 
leading to a promotion of oligodendrocyte maturation. The present study also delineates the 
cellular mechanisms of Memantine’s neuroprotective benefits.  
 
Furthermore, our data strongly suggest that DHA, TOCOPHEROL  and MEMANTINE could be 
of great interest not only in perinatal white matter damage but also as a potential neuroprotective 
strategy for myelinopathy diseases observed in adults. 
 
The data provides the proof of concept that antioxidant therapy with DHA and TOCOPHEROL  
may antagonize the effects of free-radicals that may lead to neuronal loss. The results provide 
new insights into the potential of employing n-3 TG specifically DHA as a unique long chain FA 
aiding in neonatal H/I brain injury. A number of pathways are likely involved in n-3 TG 
neuroprotection. For example, chronic administration of DHA resulted in increases of DHA 
levels in brain mitochondria. My findings suggest a need for further studies to determine if acute 
injection of DHA could be neuroprotective after stroke injury in humans. 
 
 I hypothesize that n-3 fatty acids, specifically DHA, will prove to be a “novel” and important 
therapy to treat various neuro-degenerative disorders and could decrease mortality and increase 
long-term functional recovery. 
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